Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mersana Therapeutics Inc MRSN

Healthcare Biotechnology
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed... see more

Recent & Breaking News (NDAQ:MRSN)

Mersana Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire May 28, 2020

Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study

GlobeNewswire May 27, 2020

Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting

GlobeNewswire May 15, 2020

Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study

GlobeNewswire May 14, 2020

Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program

GlobeNewswire May 13, 2020

Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536

GlobeNewswire May 13, 2020

Mersana Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire May 8, 2020

Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates

GlobeNewswire April 29, 2020

Mersana Therapeutics Announces Appointment of Martin H. Huber, M.D., to Board of Directors

GlobeNewswire April 15, 2020

Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility

GlobeNewswire April 7, 2020

Mersana Therapeutics Reports Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

GlobeNewswire March 30, 2020

Mersana Therapeutics to Report Updated Data from the XMT-1536 Phase 1 Dose Escalation Study

GlobeNewswire March 20, 2020

Mersana Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business Updates

GlobeNewswire February 28, 2020

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2019 Financial Results and Business Updates

GlobeNewswire February 21, 2020

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 18, 2020

Mersana Therapeutics Announces Pipeline Updates and 2020 Strategic Priorities and Milestones

GlobeNewswire January 10, 2020

Mersana Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 2, 2020

Mersana Therapeutics Presents New Preclinical Data from Immunosynthen Platform at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

GlobeNewswire November 8, 2019

Mersana Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Updates

GlobeNewswire November 6, 2019

Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2019 Financial Results and Business Updates

GlobeNewswire October 30, 2019